The oxygen concentrators market is evolving alongside broader trends in the respiratory devices sector, driven by strategic decisions and technological advancements.
Anticipated Impact of GLP-1 Medications on PAP Devices for Obstructive Sleep Apnea (OSA):
Reduction in OSA Severity: Effective GLP-1 medications can lead to weight loss, potentially reducing OSA severity and reliance on PAP devices
Market Dynamics: Initial demand for PAP devices is expected to remain stable, but long-term demand may decline as patients experience improved OSA symptoms and reduced dependency on these devices
Exits from the Mechanical Ventilators Market:
Medtronic: In February 2024, Medtronic announced its exit from the ventilator business, reallocating resources to more profitable segments
Philips: In January 2024, Philips discontinued several respiratory products, including ventilators and oxygen concentrators, significantly impacting the U.S. market
Market Influence: A survey by HME News in February 2024 indicated that 70% of industry respondents believe Philips' withdrawal will substantially affect the respiratory landscape, creating opportunities for other players to innovate.
Invacare:
Invacare has discontinued its respiratory product line, including HomeFill and oxygen concentrators, to realign with its mission and enhance shareholder value.
The decision follows a year-long review reflecting unfavorable market conditions. Invacare is shifting focus to key product lines that saw a 30% increase in orders in 2022.
React Health:
React Health acquired Invacare's respiratory assets, impacting the oxygen concentrator market.
Implications:
Increased market competition could lead to competitive pricing strategies
Integration of Invacare's products may cause temporary supply disruptions but offer a broader range of options for customers
React Health is poised to become a notable player in the respiratory sector, influencing competitors' market strategies.
Philips:
Philips' exit from select respiratory products, including the SimplyGo and Everflo oxygen concentrators, represents a significant market shift. A survey indicated that 70% of respondents believe this decision will greatly affect the respiratory market landscape
Strategic Innovation Opportunities: The exit of Philips creates both challenges and opportunities for other market players, prompting innovation in response to home care provider needs. Companies like GCE Healthcare are stepping in with new product offerings to fill gaps in the market
Optimistic Scenario for Competitors: The exit of Respironics presents an opportunity for companies like Inogen to strengthen their market position and financial performance by pursuing strategic initiatives
Anticipated Market Response: Other market players, including CAIRE, DeVilbiss, and Rhythm Healthcare, are expected to gain higher market share through strategic initiatives in response to the evolving landscape
Impact of Regulatory Stringency: Prolonged consent decrees faced by Invacare and Philips from the U.S. FDA highlight the stringent regulatory environment, raising concerns about the impact of regulatory scrutiny on market stability and innovation
There has been a notable transition in the U.S. oxygen concentrator market from stationary to portable devices. This shift is evidenced by the significant increase in the adoption of Portable Oxygen Concentrators (POCs), which achieved a penetration rate of 22% in 2021. This insight is derived from an analysis of U.S. Medicare claims data from 2015 to 2021, supplemented by data from Inogen's financial reports. Below are the penetration rates for different categories from 2015 to 2021:
Category |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
Stationary |
31.0% |
30.0% |
27.0% |
24.1% |
22.0% |
18.5% |
17.0% |
Ambulatory Non-POCs/ Oxygen Tanks |
61.0% |
61.0% |
62.2% |
62.0% |
60.0% |
60.5% |
61.0% |
POCs |
8.0% |
9.0% |
10.8% |
13.9% |
18.0% |
21.0% |
22.0% |
The U.S. oxygen concentrator market is witnessing a significant shift towards portable devices, driven by leading players like Inogen and emerging companies like React Health and Direct Supply. In contrast, the stationary oxygen concentrator segment is characterized by Philips' exit and the rising influence of Drive and Caire. Both market segments display a trend of increasing market fragmentation and opportunities for new entrants, indicating dynamic and competitive landscapes in the coming years.
Portable vs. Stationary Oxygen Concentrators: Notable Players Comparative Analysis
Aspect |
Portable Oxygen Concentrators (POCs) |
Stationary Oxygen Concentrators |
Market Leader |
|
Philips historically led with a 54.2% share in 2018 but exited the market by 2024. |
Notable Growth Rate (CAGR) related highlights |
Despite a modest CAGR of 1.7% from 2018-2023, Inogen's growth is expected to accelerate to 7.2% from 2024-2030. |
Drive's market share is anticipated to grow from 10.1% in 2018 to 29.1% by 2030, driven by an 8.2% CAGR from 2024-2030. Caire’s share is expected to increase from 6.2% in 2018 to 18.5% by 2030. |
Emerging Players |
React Health is expected to capture a 9.5% market share by 2030. Direct Supply has shown a robust CAGR of 25.1% from 2018-2023, with a projected growth of 10.6% from 2024-2030. |
Rhythm, Medacure, and React Health are emerging players with significant growth rates. Rhythm's market share is projected to rise from non-existent in 2018 to 8.7% by 2030. |
Mid-Sized Competitors |
Companies like Caire, Drive, and GCE have maintained steady growth. Caire’s market share is expected to grow from 3.9% in 2018 to 6.0% by 2030, with a 9.5% CAGR from 2024-2030. |
GCE and Nidek have shown steady growth.<br>- GCE's market share is expected to grow from 4.3% in 2018 to 11.1% by 2030, supported by a 5.7% CAGR from 2024-2030.<br>- Nidek's market share is projected to increase from 4.1% to 9.8% |
Market Fragmentation and Opportunities |
New entrants like Rhythm and Medacure show high growth rates and potential disruptors. |
Opportunities for niche players and new entrants as the market fragments further. |
Inogen, Inc.
Respironics (a subsidiary of Koninklijke Philips N.V.) {Effective from January 25, 2024, Philips Respironics halted the sale of their POCs, with the end of service scheduled for January 25, 2029}
React Health (Respiratory Product Line from Invacare Corporation)
Caire Medical (Acquired by Niterra Co., Ltd. formerly known as NGK SPARK PLUG CO., LTD.)
DeVilbiss Healthcare (a subsidiary of Drive Medical)
O2 Concepts
Nidek Medical Products, Inc.
GCE
Rhythm Healthcare
MedaCure Inc.
GF Health Products, Inc.
Direct Supply
Compass Health Brands
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent..."